Manuka Honey in Second- and Grafted Third-degree Burns

Clinical Application Observation of Manuka Honey in Second- and Grafted Third-degree Burns

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03048188

Enrollment

Registered

2017-02-09

Start date

2015-07-15

Completion date

2023-12-31

Last updated

2023-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Second-degree Burn, Third-Degree Burn

Brief summary

Treatment strategies of II. degree burn wounds and split-skin grafted III. degree burn wounds aim at reducing infection and improving reepithelialization. The aim of this study is to evaluate time to reepithelialization, pain, microbiology and handling of manuka honey dressings with second-degree burn wounds and split-skin grafted burn wounds.

Detailed description

In plastic and reconstructive surgery, treatment strategies of second-degree burn wounds and split-skin grafted third-degree burn wounds aim at reducing infection and improving reepithelialization. Although previous studies indicate that burn patients benefit from wound dressings containing manuka honey, only a few studies can be found. Therefore, the aim of this study is to evaluate time to reepithelialization, pain, microbiology and handling of manuka honey dressings with second-degree burn wounds and split-skin grafted burn wounds.

Interventions

OTHERwound dressing

Manuka honey wound dressing

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Consent-capable male and female patients (or guardian) * ≥18 years of age * ability to asses pain

Exclusion criteria

* Immunosuppressive Therapy * Clinical wound infection * Allergy against honey * Relationship to someone who is involved in the study design or assessment * Participation in other clinical trials

Design outcomes

Primary

Measure	Time frame	Description
Epithelialization	Up to 1 year	Rate of Epithelialization in percent

Secondary

Measure	Time frame	Description
Pain	Up to 1 year	Visual analog scale (VAS)
Microbiology	Up to 1 year	Microbiological smear is assessed by gram+, gram- or no bacterium
Handling	Up to 1 year	Scale (0-4)

Countries

Germany

Contacts

Primary ContactTobias Kisch, MD

tobias.kisch@uni-luebeck.de00494515000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026